MDM2 and rhabdomyosarcoma: A similar resistance to the three topoisomerase inhibitors was observed in p53 wild-type rhabdomyosarcoma RMS-YM cells transfected with RPL11 siRNA (Figure 2A–C), whereas there was no significant difference in sensitivity to the MDM2 inhibitor siremadlin between siRPL11- or control siRNA-transfected RMS-YM cells (Figure 2D).